"The AdvisorShares Pure US Cannabis ETF has spent the last month on a rollercoaster. After climbing to $6.45 in mid-December 2025, shares dropped 26% to around $4.80 by mid-January. The decline came despite President Trump signing an executive order easing cannabis access in late December 2025, according to Polymarket prediction market data. Yet marijuana remains a Schedule I controlled substance, as federal rescheduling did not occur in 2025."
"What to watch: Congressional movement on the SAFE Banking Act, which would allow cannabis businesses to access banking services without federal penalties. Also monitor DEA announcements regarding potential rescheduling from Schedule I to Schedule III, which would ease 280E tax burdens significantly. These developments don't follow a predictable calendar but tend to surface during budget negotiations or when key committee chairs signal support. Federal Register filings and Congressional committee schedules are your best monitoring tools."
The AdvisorShares Pure US Cannabis ETF (MSOS) experienced volatile trading, rising to $6.45 in mid-December 2025 then falling about 26% to $4.80 by mid-January. The drop occurred despite President Trump signing an executive order easing cannabis access in late December 2025; federal rescheduling did not occur and marijuana remains Schedule I. MSOS holds $921 million, charges a 0.78% expense ratio, and gains exposure to U.S. multi-state operators like Curaleaf, TerrAscend, and Trulieve through equities and total return swaps. Regulatory uncertainty, banking access limits, and IRS Section 280E tax treatment remain key performance drivers. Key developments to monitor include SAFE Banking Act progress and DEA rescheduling announcements.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]